DYRK2 and plasma cell myeloma: DYRK2 inhibitors in combination with proteasome inhibitors synergistically induced cytotoxicity [15,16], while LDN192960 alone bypassed bortezomib resistance in myeloma cells and reduced matrigel invasion in TNBC cells [16].